Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM-003 in Acute Myeloid Leukemia
NCT03426605Phase 1Completed
- Sponsor
- OrphAI Therapeutics
- Start
- Jan 2018
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LAM-003 in acute myeloid leukemia (AML), sponsored by OrphAI Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2018; status: completed.
02
Drugs
LAM-003
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03426605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426605.